Spago Nanomedical has reported positive outcome from the Data Monitoring Committeee’s review of the current data in the ongoing phase I/IIa study Tumorad-01. In addition to concluding that safety remains acceptable and that the maximum tolerated dose has not yet been reached, the DMC considers the observations of visible uptake of the radiopharmaceutical candidate ¹⁷⁷Lu-SN201 in tumor as Proof-of-Concept in cancer patients. Following the review, the company has been recommended to increase the dose. This represent a key step forward for the program, and BioStock reached out to CEO Mats Hansen for a comment.